ACSH's Dr. Elizabeth Whelan is among the scientific experts who contributed to the "Second Opinion" feature on the FDA s Bad Ad program in the Manhattan Institute's Medical Progress Today. She wrote:
Ultimately, encouraging colleagues to report on colleagues is unprofessional and can only foster adversarial relationships between physicians and pharmaceutical companies. Instead, why doesn't the FDA try training a small group of doctors and paying them a modest honorarium to monitor ads?
If you enjoyed ACSH s Jeff Stier s contribution Wednesday to National Review Online s blog The Corner, we recommend reading Jay Nordlinger s commentary on the accomplishments of Nobel laureate and ACSH founding trustee Dr.Norman Borlaug, featured on The Feeder of yesterday s Corner.
And if you're interested in hearing even more from Stier, follow him on Twitter at http://twitter.com/JeffACSH or on Facebook.